SEC Form 4 · accession 0001144204-18-037212
CASI Pharmaceuticals, Inc. · CASI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Franklin Cary Salisbury Jr.
Director
Period of report
Jun 29, 2018
Accepted (ET)
Jul 3, 2018 · 3:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000895051
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $8.23 | Jun 29, 2018 | A | 35,000 | A | — | Jun 29, 2028 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1Stock option award will vest ratably quarterly to the end of one year.